Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues

12Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

New carbamoylpyridine and carbamoylpiperidine analogues containing nipecotic acid scaffold were designed, synthesized, and evaluated for their platelet aggregation inhibitory activity. Molecular modeling investigation was performed and the impact of lipophilicity on activity was also discussed. Structure activity relationship among this series was obtained. N 1-[1-(4-bromobenzyl)-3-piperidinocarbonyl]- N4-(2- chlorophenyl)-piperazine hydrobromide (20), and 1,4-bis-[3-[N 4-(2-chlorophenyl)-N1-(piperazinocarbonyl)]- piperidin-1-yl-methyl]-benzene dibromide (30) are the most active antiplatelet aggregating compounds in this study, both at concentration of 0.06 lM. © Springer Science+Business Media, LLC 2010.

Cite

CITATION STYLE

APA

Youssef, K. M., Al-Omar, M. A., El-Subbagh, H. I., Abou-zeid, L. A., Abdel-Gader, A. G. M., Haress, A. G. M., & Al-Tuwaijri, A. S. (2011). Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues. Medicinal Chemistry Research, 20(7), 898–911. https://doi.org/10.1007/s00044-010-9411-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free